Literature DB >> 10204573

HIV-1-induced neuronal injury in the developing brain.

L G Epstein1, H A Gelbard.   

Abstract

HIV-1 infection of the nervous system causes neuronal injury and death, resulting in cognitive, motor, and behavioral dysfunction in both adults and children. In infants a characteristic feature of HIV-1 infection is impaired brain growth resulting in secondary microcephaly with onset between 2 and 4 months of age. This post-natal period of brain development is particularly vulnerable to excitotoxic neuronal injury due to the active synaptogenesis and pruning that takes place at this age associated with over-expression of excitatory amino acid (EAA) receptors. HIV-1 infection of brain microglia and perivascular macrophages results in chronic inflammation manifest pathologically as diffuse microglial activation and reactive astrogliosis. Several inflammatory products of activated microglia, including tumor necrosis factor alpha (TNF-alpha) and platelet-activating factor (PAF) have been shown to act as neuronal toxins. This toxic effect can be antagonized by blocking NMDA (or AMPA) glutamate receptors, suggesting that (weak) excitotoxicity leads to oxidative stress, neuronal injury, and apoptosis. HIV-1 infection and chronic inflammation may also contribute disruption of the blood-brain barrier and could result in further entry into the CNS of toxic viral or cellular products or additional HIV-1-infected cells. We hypothesize that prolonged microglial activation during HIV-1 infection underlies the neuronal injury and impaired brain growth in affected infants. Further investigation of the interaction between HIV-1-infected/activated microglia and developing neurons seems warranted. The current understanding of HIV neuropathogenesis implies that therapeutic strategies should target the sustained immune activation in microglia, attempt to repair the integrity of the blood-brain barrier, and provide "neuroprotection" from excitotoxic neuronal injury.

Entities:  

Mesh:

Year:  1999        PMID: 10204573     DOI: 10.1002/jlb.65.4.453

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  24 in total

1.  Chronic CXCL10 alters the level of activated ERK1/2 and transcriptional factors CREB and NF-kappaB in hippocampal neuronal cell culture.

Authors:  Hilda Bajova; Thomas E Nelson; Donna L Gruol
Journal:  J Neuroimmunol       Date:  2008-03-10       Impact factor: 3.478

2.  The chemokine CXCL12 and the HIV-1 envelope protein gp120 regulate spontaneous activity of Cajal-Retzius cells in opposite directions.

Authors:  Ivan Marchionni; Michael Beaumont; Gianmaria Maccaferri
Journal:  J Physiol       Date:  2012-04-02       Impact factor: 5.182

3.  Productive infection of human neural progenitor cells by R5 tropic HIV-1: opiate co-exposure heightens infectivity and functional vulnerability.

Authors:  Joyce M Balinang; Ruturaj R Masvekar; Kurt F Hauser; Pamela E Knapp
Journal:  AIDS       Date:  2017-03-27       Impact factor: 4.177

4.  HIV-1 Glycoprotein 120 Enhancement of N-Methyl-D-Aspartate NMDA Receptor-Mediated Excitatory Postsynaptic Currents: Implications for HIV-1-Associated Neural Injury.

Authors:  Yan Zhou; Jianuo Liu; Huangui Xiong
Journal:  J Neuroimmune Pharmacol       Date:  2016-12-22       Impact factor: 4.147

Review 5.  T-Cells and excitotoxicity: HIV-1 and other neurodegenerative disorders.

Authors:  Muhammad Mukhtar; Edward Acheampong; Zahida Parveen; Roger J Pomerantz
Journal:  Neuromolecular Med       Date:  2005       Impact factor: 3.843

6.  HIV-associated CD4+/CD8+ depletion in infancy is associated with neurometabolic reductions in the basal ganglia at age 5 years despite early antiretroviral therapy.

Authors:  Kenneth K Mbugua; Martha J Holmes; Mark F Cotton; Eva-Maria Ratai; Francesca Little; Aaron T Hess; Els Dobbels; Andre J W Van der Kouwe; Barbara Laughton; Ernesta M Meintjes
Journal:  AIDS       Date:  2016-06-01       Impact factor: 4.177

7.  Human microglial cell isolation from adult autopsy brain: brain pH, regional variation, and infection with human immunodeficiency virus type 1.

Authors:  Kimberly Schuenke; Benjamin B Gelman
Journal:  J Neurovirol       Date:  2003-06       Impact factor: 2.643

8.  Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS.

Authors:  Huanyu Dou; Cassi B Grotepas; JoEllyn M McMillan; Christopher J Destache; Mahesh Chaubal; Jane Werling; James Kipp; Barrett Rabinow; Howard E Gendelman
Journal:  J Immunol       Date:  2009-06-17       Impact factor: 5.422

9.  Association of maternal antiretroviral use with microcephaly in children who are HIV-exposed but uninfected (SMARTT): a prospective cohort study.

Authors:  Paige L Williams; Cenk Yildirim; Ellen G Chadwick; Russell B Van Dyke; Renee Smith; Katharine F Correia; Alexandria DiPerna; George R Seage; Rohan Hazra; Claudia S Crowell
Journal:  Lancet HIV       Date:  2019-11-15       Impact factor: 12.767

10.  Methamphetamine enhances cell-associated feline immunodeficiency virus replication in astrocytes.

Authors:  Mikhail A Gavrilin; Lawrence E Mathes; Michael Podell
Journal:  J Neurovirol       Date:  2002-06       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.